Stoke Therapeutics, Inc. financial data

Symbol
STOK on Nasdaq
Industry
Pharmaceutical Preparations
Location
45 Wiggins Avenue, Bedford, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ASOthera Pharmaceuticals, Inc. (to 11/24/2014)
Latest financial report
Q1 2024 - May 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 780 % -12.8%
Debt-to-equity 40.3 % +15%
Return On Equity -65.5 % -36.8%
Return On Assets -46.7 % -31.7%
Operating Margin -1.51 K % -111%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.3 M shares +4.79%
Common Stock, Shares, Outstanding 46.5 M shares +5.26%
Entity Public Float 290 M USD -2.36%
Common Stock, Value, Issued 5 K USD +25%
Weighted Average Number of Shares Outstanding, Basic 46.2 M shares +8.72%
Weighted Average Number of Shares Outstanding, Diluted 46.2 M shares +8.72%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 7.84 M USD -46.1%
Research and Development Expense 85 M USD +7.34%
General and Administrative Expense 41.3 M USD +4.24%
Operating Income (Loss) -118 M USD -13.6%
Nonoperating Income (Expense) 9.93 M USD +87.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -109 M USD -9.67%
Earnings Per Share, Basic -2.42 USD/shares +2.02%
Earnings Per Share, Diluted -2.42 USD/shares +2.02%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 179 M USD -6.18%
Other Assets, Current 3.56 M USD -39.5%
Assets, Current 193 M USD -28.5%
Property, Plant and Equipment, Net 5.28 M USD -22.3%
Operating Lease, Right-of-Use Asset 6.06 M USD +44.2%
Assets 205 M USD -27.2%
Accounts Payable, Current 2.1 M USD -51.1%
Liabilities, Current 35.6 M USD +12.9%
Operating Lease, Liability, Noncurrent 4.13 M USD +97%
Other Liabilities, Noncurrent 4.21 M USD +82.7%
Liabilities 64.8 M USD -4.61%
Accumulated Other Comprehensive Income (Loss), Net of Tax -24 K USD +98%
Retained Earnings (Accumulated Deficit) -428 M USD -33.9%
Stockholders' Equity Attributable to Parent 140 M USD -34.4%
Liabilities and Equity 205 M USD -27.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.6 M USD -15%
Net Cash Provided by (Used in) Financing Activities 1.72 M USD -96.2%
Net Cash Provided by (Used in) Investing Activities 9.99 M USD -81.2%
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 46.5 M shares +5.26%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.9 M USD -117%
Deferred Tax Assets, Valuation Allowance 133 M USD +36.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 133 M USD +36.1%
Operating Lease, Liability 6.34 M USD +40.9%
Depreciation 563 K USD -5.7%
Payments to Acquire Property, Plant, and Equipment 12 K USD -92.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -108 M USD -9.16%
Lessee, Operating Lease, Liability, to be Paid 7.18 M USD +53.4%
Property, Plant and Equipment, Gross 12.5 M USD +14.8%
Operating Lease, Liability, Current 2.21 M USD -7.95%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.66 M USD +2.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.96 M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +107%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 846 K USD +360%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.56 M USD +1391%
Deferred Tax Assets, Operating Loss Carryforwards 52.6 M USD -8.84%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 569 M USD +6.45%
Share-based Payment Arrangement, Expense 24.8 M USD +4.27%